Syngene International Limited (SYNGENE.NS)
INR 627.95
(-0.96%)
INR 627.95
(-0.96%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -83 Million INR | -101.14% |
| 2022 | 7.25 Billion INR | -4.59% |
| 2021 | 7.6 Billion INR | 33.23% |
| 2020 | 5.7 Billion INR | -1.69% |
| 2019 | 5.8 Billion INR | -10.4% |
| 2018 | 6.48 Billion INR | 21.21% |
| 2017 | 5.34 Billion INR | -10.62% |
| 2016 | 5.98 Billion INR | 18.76% |
| 2015 | 5.03 Billion INR | 942.86% |
| 2014 | 483 Million INR | -23.7% |
| 2013 | 633 Million INR | 967.12% |
| 2012 | -73 Million INR | -110.6% |
| 2011 | 689 Million INR | -58.77% |
| 2010 | 1.67 Billion INR | -15.65% |
| 2009 | 1.98 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 16.58 Billion INR | 20079.52% |
| 2024 Q2 | -614 Million INR | -74.9% |
| 2023 Q4 | -83 Million INR | -101.39% |
| 2023 Q1 | 6.2 Billion INR | -14.57% |
| 2023 Q2 | 6.64 Billion INR | 7.21% |
| 2023 Q3 | 5.96 Billion INR | -10.25% |
| 2023 FY | -83 Million INR | -101.14% |
| 2022 Q3 | 8.81 Billion INR | 3.68% |
| 2022 Q4 | 7.25 Billion INR | -17.64% |
| 2022 FY | 7.25 Billion INR | -4.59% |
| 2022 Q1 | 6.09 Billion INR | -19.89% |
| 2022 Q2 | 8.49 Billion INR | 39.47% |
| 2021 FY | 7.6 Billion INR | 33.23% |
| 2021 Q2 | 7.17 Billion INR | 68.36% |
| 2021 Q4 | 7.6 Billion INR | -6.75% |
| 2021 Q3 | 8.15 Billion INR | 13.7% |
| 2021 Q1 | 4.26 Billion INR | -25.36% |
| 2020 Q3 | 13.1 Billion INR | 235.14% |
| 2020 FY | 5.7 Billion INR | -1.69% |
| 2020 Q2 | 3.91 Billion INR | -61.66% |
| 2020 Q1 | 10.19 Billion INR | 75.63% |
| 2020 Q4 | 5.7 Billion INR | -56.43% |
| 2019 Q4 | 5.8 Billion INR | -32.55% |
| 2019 FY | 5.8 Billion INR | -10.4% |
| 2019 Q1 | 11.52 Billion INR | 77.89% |
| 2019 Q3 | 8.6 Billion INR | 34.12% |
| 2019 Q2 | 6.41 Billion INR | -44.32% |
| 2018 FY | 6.48 Billion INR | 21.21% |
| 2018 Q2 | 7.5 Billion INR | -33.33% |
| 2018 Q3 | 8.51 Billion INR | 13.57% |
| 2018 Q1 | 11.25 Billion INR | 110.42% |
| 2018 Q4 | 6.48 Billion INR | -23.92% |
| 2017 Q4 | 5.34 Billion INR | 7.8% |
| 2017 Q2 | 6.69 Billion INR | -37.32% |
| 2017 FY | 5.34 Billion INR | -10.62% |
| 2017 Q3 | 4.96 Billion INR | -25.88% |
| 2017 Q1 | 10.67 Billion INR | 78.49% |
| 2016 Q3 | 10.84 Billion INR | 312.94% |
| 2016 Q2 | 2.62 Billion INR | -73.63% |
| 2016 FY | 5.98 Billion INR | 18.76% |
| 2016 Q1 | 9.96 Billion INR | 97.8% |
| 2016 Q4 | 5.98 Billion INR | -44.86% |
| 2015 FY | 5.03 Billion INR | 942.86% |
| 2015 Q3 | 1.83 Billion INR | 142.35% |
| 2015 Q2 | 755.1 Million INR | -71.15% |
| 2015 Q1 | 2.61 Billion INR | 441.82% |
| 2015 Q4 | 5.03 Billion INR | 175.25% |
| 2014 Q4 | 483 Million INR | 8.3% |
| 2014 FY | 483 Million INR | -23.7% |
| 2014 Q1 | 4.43 Billion INR | 0.0% |
| 2014 Q3 | 446 Million INR | 0.0% |
| 2013 FY | 633 Million INR | 967.12% |
| 2012 FY | -73 Million INR | -110.6% |
| 2011 FY | 689 Million INR | -58.77% |
| 2010 FY | 1.67 Billion INR | -15.65% |
| 2009 FY | 1.98 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Biocon Limited | 140.18 Billion INR | 100.059% |
| Blue Jet Healthcare Limited | -830.93 Million INR | 90.011% |
| Concord Biotech Limited | -54.04 Million INR | -53.576% |
| Dishman Carbogen Amcis Limited | 18.99 Billion INR | 100.437% |
| Jubilant Ingrevia Limited | 6.6 Billion INR | 101.256% |
| Lyka Labs Limited | 527.01 Million INR | 115.749% |
| Panacea Biotec Limited | -1.18 Billion INR | 92.995% |
| Piramal Pharma Limited | 42.27 Billion INR | 100.196% |
| SMS Lifesciences India Limited | 992.31 Million INR | 108.364% |
| Supriya Lifescience Limited | -694.68 Million INR | 88.052% |
| TAKE Solutions Limited | 361.37 Million INR | 122.968% |
| Zota Health Care Limited | 942.79 Million INR | 108.804% |